Medicinova Inc (MNOV) Stock Price & Analysis
Medicinova Inc (MNOV) fell 2.31% to USD 1.27 as of June 10, 2026 at 08:40 UTC, according to Nexqual real-time market data.
MNOV last closed at USD 1.3; the session ranged USD 1.27–1.3 on volume of 14,872 shares. Market capitalization is $62.51M, with a 52-week range of USD 1.17–1.96 (NGM). Source: Nexqual, June 10, 2026 at 08:40 UTC.
Key Statistics (as of June 10, 2026 at 08:40 UTC)
| Price | USD 1.27 |
|---|---|
| Change | ▼ 2.31% (down) |
| Previous Close | USD 1.3 |
| Open | USD 1.29 |
| Day Range | USD 1.27 – 1.3 |
| 52-Week Range | USD 1.17 – 1.96 |
| Volume | 14,872 shares |
| Market Cap | $62.51M |
| Exchange | NGM |
Technical Analysis (MNOV)
Nexqual's technical model rates MNOV "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.26 (neutral) |
| vs SMA50 | Below (USD 1.39) |
| MACD | -0.02 (negative) |
Analyst Ratings (MNOV)
Wall Street analysts rate MNOV "Strong Buy" based on 3 analysts, with a mean price target of USD 9 (range USD 6–11), per Nexqual as of June 10, 2026 at 08:40 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 9 |
| High Target | USD 11 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (MNOV)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $75,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.05 vs est -0.07 ▲ beat |
| 2025-12-31 | USD -0.05 vs est -0.1 ▲ beat |
| 2025-09-30 | USD -0.06 vs est -0.12 ▲ beat |
| 2025-06-30 | USD -0.07 vs est -0.12 ▲ beat |
Source: Nexqual, June 10, 2026 at 08:40 UTC.
Financials & Fundamentals (MNOV)
| Total Revenue | $596,641 |
|---|---|
| Gross Margin | +8.03% |
| Operating Margin | -1516.60% |
| Profit Margin | +0.00% |
| ROE | -26.24% |
| Debt / Equity | 0.42 |
| Current Ratio | 9.09 |
| Total Cash | $27.33M |
| Total Debt | $165,198 |
| Free Cash Flow | $-5.96M |
Source: Nexqual, June 10, 2026 at 08:40 UTC.
Financial Health Score (MNOV)
Nexqual rates Medicinova Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:40 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $27M cash, no debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -26%, ROA -17.0% |
Ownership (MNOV)
| Insider Ownership | +2.88% |
|---|---|
| Institutional Ownership | +11.04% |
| Shares Outstanding | 49.22M |
| Float | 42.26M |
| Short % of Float | +0.36% |
Source: Nexqual, June 10, 2026 at 08:40 UTC.
Leadership (MNOV)
Medicinova Inc is led by Yuichi Iwaki (age 75), Co-Founder, President, CEO & Chairman, per Nexqual as of June 10, 2026 at 08:40 UTC.
| Co-Founder, President, CEO & Chairman | Yuichi Iwaki (age 75) |
|---|---|
| Senior VP, Chief Medical Officer & Director | Kazuko Matsuda M.D., M.P.H. (age 59) |
| CFO & Principal Financial Officer | Jason J. Kruger (age 47) |
Major Backers & Investors (MNOV)
Notable institutional backers of Medicinova Inc include Essex Woodlands Management Inc., Citigroup Inc., Fidelity, according to Nexqual as of June 10, 2026 at 08:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Essex Woodlands Management Inc. | 2.25% |
| Citigroup Inc. | 1.29% |
| Fidelity | 0.89% |
| UBS Group AG | 0.45% |
| Renaissance Technologies | 0.39% |
| Barclays Plc | 0.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.05% |
| BlackRock | 1.66% |
| Geode Capital | 1.1% |
| State Street | 0.39% |
Source: Nexqual, June 10, 2026 at 08:40 UTC.
From Medicinova Inc's Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
- It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
- The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NERV | Minerva Neurosciences, Inc | USD 4.74 | ▼ 4.44% |
| ENTX | Entera Bio Ltd. | USD 1.22 | ▲ 3.39% |
| LITS | Lite Strategy, Inc. | USD 0.76 | ▲ 0.84% |
| ACIU | AC Immune SA | USD 2.26 | ▲ 0.44% |
| PRQR | ProQR Therapeutics N.V. | USD 1.47 | ▼ 2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:40 UTC. This page is informational and not investment advice.